Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H24FN5O6.ClH |
Molecular Weight | 497.905 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(F)=C(C=C2)N3CCN(CC4=CC=C(O4)[N+]([O-])=O)CC3
InChI
InChIKey=XYGNKPXLGBABKJ-LMOVPXPDSA-N
InChI=1S/C21H24FN5O6.ClH/c1-14(28)23-11-17-13-26(21(29)33-17)15-2-4-19(18(22)10-15)25-8-6-24(7-9-25)12-16-3-5-20(32-16)27(30)31;/h2-5,10,17H,6-9,11-13H2,1H3,(H,23,28);1H/t17-;/m0./s1
Molecular Formula | C21H24FN5O6 |
Molecular Weight | 461.4436 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:03:30 GMT 2023
by
admin
on
Sat Dec 16 11:03:30 GMT 2023
|
Record UNII |
X26J4H4W8H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
392659-39-1
Created by
admin on Sat Dec 16 11:03:30 GMT 2023 , Edited by admin on Sat Dec 16 11:03:30 GMT 2023
|
PRIMARY | |||
|
6918631
Created by
admin on Sat Dec 16 11:03:30 GMT 2023 , Edited by admin on Sat Dec 16 11:03:30 GMT 2023
|
PRIMARY | |||
|
X26J4H4W8H
Created by
admin on Sat Dec 16 11:03:30 GMT 2023 , Edited by admin on Sat Dec 16 11:03:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
The chemical synthesis of Ranbezolid hydrochloride. The antibacterial activity of RBx-7644 is due to the 5(S)-acetamidomethyl configuration at the oxazolidinone ring, and thus, asymmetric synthesis of only the 5(S)-enantiomer was desirable.
|